- Quest to provide comprehensive dialysis-related laboratory and
water testing services to Fresenius Medical Care owned and
affiliated clinics in the United
States
BAD HOMBURG, Germany and SECAUCUS, N.J., Feb. 24,
2025 /PRNewswire/ -- Fresenius Medical Care
(XETRA: FME; NYSE: FMS), the world's leading provider of products
and services for individuals with renal disease, and Quest
Diagnostics (NYSE: DGX), a leading provider of diagnostic
information services, today announced that, under terms of a
definitive acquisition agreement, Quest will acquire select assets
of FME's wholly owned Spectra Laboratories, a leading
provider of renal-specific laboratory testing services in the U.S.
In addition, under a separate agreement, Quest will provide
comprehensive laboratory services related to end-stage kidney
disease (ESKD) and specialized water testing for patients and
providers served by dialysis centers operated by Fresenius Medical
Care and its wholly owned and joint-venture partners in
the United States.
By acquiring select laboratory assets from FME, Quest will add
dialysis-related water testing, a new capability, to Quest's
comprehensive portfolio. The arrangement will enable FME to gain
operational efficiencies and allow FME and other providers and
patients at dialysis clinics to benefit from Quest's clinical
leadership and diagnostic innovation in chronic kidney disease and
transplantation services. It will also leverage Quest's national
scale, as multiple Quest laboratories spread across the U.S. will
provide testing for nearby dialysis clinics, reducing
transportation time and speeding results reporting for some test
services. Quest expects to perform testing across several of its
laboratories during lower-volume daytime hours, optimizing the
return on capital invested into its laboratory network.
Financial terms were not disclosed. The acquisition is expected
to close in the second half of 2025, pending customary state
regulatory reviews. The transition of services is expected to be
complete by early 2026.
"This transaction is part of our comprehensive portfolio
optimization strategy to drive operational efficiencies and will
provide enhanced experiences for patients and our clinical
employees by integrating Quest Diagnostic's industry-leading
expertise in laboratory medicine into our dialysis centers. This
agreement is a step forward to allow us to remain focused on our
core business of providing world-class dialysis care to every
patient, every day," said Helen
Giza, Chief Executive Officer of Fresenius Medical
Care. "Much like Fresenius Medical Care, Quest Diagnostics is
passionate about creating a healthier future for patients. These
shared values, along with Quest's proven track record for quality
care and service, make us confident that they are the right company
to continue to deliver a high-quality experience to our patients,
physician partners, and clinical staff."
"Our relationship with Fresenius Medical Care will extend our
industry-leading test portfolio in chronic kidney disease, one of
the nation's most prevalent chronic diseases, to include
dialysis-related laboratory and water testing," said Jim Davis, Chairman, CEO and President, Quest
Diagnostics. "It will also optimize Quest's national scale to bring
high-quality laboratory services closer to FME's dialysis clinics
and the patients under their care across the United States."
Fresenius Medical Care recently successfully finished year two
of a three-year strategic turnaround and transformation plan.
Focusing on businesses and markets with the best strategic fit and
greatest scale and sustainable profitable growth potential,
Fresenius Medical Care is continuing to execute against its
portfolio optimization plan to divest non-core and dilutive
assets.
Chronic kidney disease affects about 35.5 million people,
or 14%, of the U.S. population, making it one of the nation's
10 most prevalent and costly chronic diseases in the U.S. Up
to 9 in 10 adults who have CKD are not aware that they have the
disease. Once the disease has progressed to end-stage kidney
disease (ESKD), patients typically require transplant or dialysis.
More than 800,000 people in the U.S. receive dialysis.
Dialysis requires periodic lab testing to manage the disease as
well as testing water for contaminants.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products
and services for individuals with renal diseases of which around
4.1 million patients worldwide regularly undergo dialysis
treatment. Through its network of 3,732 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approx. 308,000
patients around the globe. Fresenius Medical Care is also the
leading provider of dialysis products such as dialysis machines or
dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock
Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website
at www.freseniusmedicalcare.com.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a
healthier world, one life at a time. We provide diagnostic insights
from the results of our laboratory testing to empower people,
physicians and organizations to take action to improve health
outcomes. Derived from one of the world's largest databases of
de-identifiable clinical lab results, Quest's diagnostic insights
reveal new avenues to identify and treat disease, inspire healthy
behaviors and improve healthcare management. Quest Diagnostics
annually serves one in three adult Americans and half the
physicians and hospitals in the United
States, and our more than 55,000 employees understand that,
in the right hands and with the right context, our diagnostic
insights can inspire actions that transform lives and create a
healthier world. www.QuestDiagnostics.com.
Disclaimer:
This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to the COVID-19 pandemic
results of clinical studies, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties
are detailed in Fresenius Medical Care's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care
does not undertake any responsibility to update the forward-looking
statements in this release.
FME Media contact
Christine
Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
FME Contact for analysts and investors
Dr.
Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com
Quest Media contact
Jen
Petrella
T +1 973-520-2800
mediacontact@QuestDiagnostics.com
Quest Contact for analysts and investors
Shawn Bevec
T +1 973-520-2900
shawn.c.bevec@questdiagnostics.com
www.questdiagnostics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-announces-divestment-of-select-laboratory-assets-to-quest-diagnostics-302383348.html
SOURCE Fresenius Medical Care Holdings, Inc.
